<DOC>
	<DOCNO>NCT01701752</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity FP-01.1 FP-01.1 reformulate adjuvant ( FP-01.1-Adjuvant ) relatively healthy subject 65 74 year age , subject representative target population . Both formulation administer alone concomitantly Trivalent Inactivated Influenza Virus ( TIV ) vaccine .</brief_summary>
	<brief_title>Influenza A Vaccine ( FP-01.1 ) Formulated With Without Adjuvant , Presence Absence Single Administration Trivalent Inactivated Influenza Virus Vaccine Older Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 65 74 year inclusive time consent Female subject postmenopausal ( menses least 2 year ) therefore nonchild bear potential Male subject willing comply applicable contraceptive requirement protocol , e.g . must agree refrain father child safety follow visit . Male subject need use contraception partner menopause , hysterectomy bilateral oophorectomy . If male subject 's partner child bear potential , male subject must agree use barrier method ( condom ) method birth control addition contraceptive measure normally take partner , safety follow visit . Satisfactory medical assessment clinically significant relevant abnormality medical history , physical examination , vital sign , ECG laboratory evaluation ( haematology &amp; biochemistry ) assess Investigator relation age patient . An understanding , ability willingness fully comply study procedure restriction Ability provide write , personally sign date informed consent participate study . The subject BMI &lt; 35 . As result medical screening process , Principal Investigator Co Investigator considers subject unfit study . Women childbearing potential Clinically significant , uncontrolled , current , chronic recurrent disease , deem Investigator , ( e.g . cardiovascular , respiratory , endocrine , renal , liver , gastrointestinal , autoimmune , immune suppression , malignancy condition ) could affect action , absorption disposition IMP could affect clinical laboratory assessment . Significant illness judge Principal Investigator CoInvestigator within 2 week first dose IMP . Subjects history allergy allergic condition include anaphylactic reaction , asthmatic , hay fever , allergy egg product eczema sufferer require medication opinion Principal Investigator Co Investigator affect participation study . Subjects receive medication affect immune system include systemic steroid dose great 5mg patient chronic medication dose stable least 3 month . Inhaled topical steroid allow . Known suspected intolerance hypersensitivity IMP , closely related compound state ingredient . Male subject consume 21 unit alcohol per week female subject consume 14 unit alcohol per week . A positive HIV antibody screen , Hepatitis B surface antigen , Hepatitis B core antibody , Hepatitis C antibody screen Subjects significant scarring , tattoo , abrasion , cut infection , opinion Investigator could interfere evaluation injection site local reaction , deltoid region arm dose site . Donation blood blood product ( e.g . plasma , platelet ) within 90 day prior intention donate blood entire study . Use another investigational medicinal product within 90 day prior receive first dose IMP intention enrol another clinical study throughout entire study include follow period . Subject suspected recent ( ≤6 month ) experience influenzalike illness ( fever [ &gt; 37.8ºC ] cough and/or sore throat &gt; 2 day absence know cause influenza ) Subjects receive flu vaccine last 6 month Any clinically significant abnormality , opinion Principal Investigator CoInvestigator , electrocardiogram ( ECGs ) In addition , subject , complete medical history questionnaire take part consent study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Influenza A</keyword>
</DOC>